Saturday, February 16, 2019

Hemispherx Biopharma Releases Rintatolimod in EAP-program to Dutch Pancreatic Cancer Patients

Rintatolimod (Ampligen®; Hemispherx Biopharma) is a mismatched, double-stranded RNA molecule with immunomodulatory and antiviral properties. The drug acts as a Toll-like Receptor 3 (TLR3) agonists. TLR3s have been extensively used as adjuvants for anticancer vaccines. Rintatolimod stimulates the production of interferons and tumor necrosis factors and has shown to raise natural killer cell function. In a statement, Hemispherx Biopharma the...

Phase III Trial of Anti-PD-1 Antibody Tislelizumab + Chemotherapy Initiated as Treatment for NSCLC

BeiGene, a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs, has dosed the first patient dosed in a Phase III clinical trial of tislelizumab, also known as BGB-A317,an investigational anti-PD-1 antibody, combined with chemotherapy, as a potential first-line treatment in China for patients with Stage IIIB or IV squamous non-small cell lung cancer (NSCLC). In...

Clinigen Group Acquires Global Rights to Novartis’ Proleukin®

The United Kingdom-based Clinigen Group has bought the global rights to Proleukin®, also known as Aldesleukin (recombinant interleukin-2; rIL2) outside the USA from Swiss Pharmaceutical company Novartis. Financial details of the agreement have not been disclosed. Indication Initially called T cell growth factor or TCGF, Interleukin-2 (IL-2), a type of cytokine signaling molecule, was one of the first interleukins to be...

Griffith R. Harsh IV to Lead Neurological Surgery at UC Davis

Renowned surgeon, scientist and educator Griffith Rutherford Harsh IV has been selected as chair of the Department of Neurological Surgery and the Julian R. Youmans Chair in Neurological Surgery at UC Davis Health. He begins his new position July 1, 2018 Currently, Harsh is vice chair of the Department of Neurosurgery at Stanford University, where he also is director of...

AbbVie and Rice University establish Research Accelerator to Advance Novel Cancer Therapies

AbbVie and Rice University have entered into a joint research collaboration to establish the K.C. Nicolaou Research Accelerator. According to both AbbVie and Rice University, the research at the Accelerator will focus on synthesizing novel cytotoxic agents for use in the fight against a number of cancer. The collaboration is expected to complement AbbVie's existing expertise in oncology discovery and...

Servier Acquires Shire’s Oncology Unit – Significantly Strengthening the Group’s Oncology Portfolio

Earlier this week the French pharmaceutical company Servier, announced that it has entered into a definitive agreement with Shire, a leading global biotechnology company focused on rare diseases, to acquire its Oncology business for $2.4 billion. The transaction is expected to be finalized in the second or third quarter of 2018 after obtaining authorizations from the competent competition authorities. The...

Congress Called Upon to Protect Medical Research Funding From Sequestration Cuts

Earlier this month, during the Annual Meeting of the American Society of Clinical Oncology(ASCO) being held in Chicago from may 31 - June 4, 2013, ASCO president Sandra M. Swain, MD, FACP (photo), recognized the significant progress toward modernizing clinical cancer research but also warned that advances against cancer could stagnate as a result of recent cuts to U.S....

ADC Therapeutics and Genmab Agree to Develop Novel Antibody-drug Conjugate

Earlier this week Swiss-based oncology drug development companyADC Therapeutics Sarland DanishGenmab A/Sagreed to develop a new antibody-drug conjugate (ADC)combiningHuMax®-TAC antibody and a PBD-based warhead and linker technology. The companies have been conducting in vitro and in vivo studies since 2012 to investigate different warhead and linker combinations with HuMax-TAC, and are now starting pre-IND preclinical development. The new product...

Incretin Mimetic Drugs may be Linked to an Increased Risk of Pancreatitis and Pancreatic Cancer – First Lawsuit Filed in New York

Earlier this year the FDA started evaluating unpublished reports from a group of academic researchers suggesting an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with Type 2 Diabetes (T2DM) treated with a class of drugs called incretin mimetics.In recent years a class of drugs has been introduced for treatment of T2DM that...

U.S. FDA Approves Lenalidomide for the Treatment of Patients with Mantle Cell Lymphoma (MCL)

On June 5, 2013, the U. S. Food and Drug Administration approved lenalidomide capsules (Revlimid®, Celgene Corporation), for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib (Velcade®,Millennium Pharmaceuticals, a wholly-owned subsidiary of Takeda Pharmaceutical Company).Mantle cell lymphoma (MCL) is a rare subtype of...

right side

ads

Related articles